Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Lung Diseases(Electronic Edition) ›› 2020, Vol. 13 ›› Issue (02): 213-217. doi: 10.3877/cma.j.issn.1674-6902.2020.02.018

• Original Article • Previous Articles     Next Articles

Effects of recombinant human thrombopoietin in improving myocardial injury in patients with sepsis

Yun Xie1, Zhigang Zhou1,(), Rui Tian1, Wei Jin1, Hui Xie1, Jiang Du1, Yijun Hou1, Xiaolei Teng1, Ruilan Wang1,()   

  1. 1. Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201600, China
  • Received:2019-12-15 Online:2020-04-25 Published:2021-07-22
  • Contact: Zhigang Zhou, Ruilan Wang

Abstract:

Objective

To investigate the changes of myocardial injury markers, cardiac functions and inflammatory cytokines in the patients with sepsis treated with recombinant human thrombopoietin (rhTPO), and to determine its effects on the clinical prognosis.

Methods

In this study, the patients with sepsis who met Sepsis 3.0 diagnostic criteria were collected from the Emergency Critical Care Medical Ward of Shanghai First People′s Hospital from January 2016 to April 2019 by retrospective observation method. According to whether they were treated with rhTPO, they were divided into an rhTPO group and a control group. The basic information, clinical data, inflammatory factors, indexes of immune functions, and prognosis conditions were collected. The main monitoring indexes for the patients were the myocardial injury marker Troponin I (TnI) and the cardiac function marker brain natriuretic peptide (BNP). The secondary monitoring indexes were inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). Student′s t test was employed to treat the normal distribution data, the nonparametric test was employed to treat the abnormal distribution data, and Chi square test or Fisher inspection methods were employed to treat the counting data. And differences between the two groups were compared.

Results

A total of 186 patients with sepsis were included in this study, including 26 patients in the rhTPO group and 160 patients in the control group. On the 7th day of treatment of rhTPO, TnI (0.2517±0.1347 g/L in the rhTPO group vs. 0.6471±0.4145 g/L in the control group, P=0.006), BNP (306.1±53.52 pg/ml in the rhTPO group vs. 529.4±251.1 pg/ml in the control group, P<0.0001), IL-6 (357.1±84.71 pg/ml in the rhTPO group vs. 843.3±514.0 pg/ml in the control group, P<0.0001), and TNF-α (5.850±1.621 pg/ml in the rhTPO group vs. 9.771±9.051 pg/ml in the control group, P<0.0001) showed significant decreases in the patients of the rhTPO group compared with the patients in the control group.

Conclusion

The rhTPO can improve the myocardial injury, the cardiac functions and the inflammatory indexes of sepsis.

Key words: Recombinant human thrombopoietin, Sepsis, Myocardial injury, Cardiac function

京ICP 备07035254号-28
Copyright © Chinese Journal of Lung Diseases(Electronic Edition), All Rights Reserved.
Tel: 023-65425691 E-mail: xqcjld@163.com
Powered by Beijing Magtech Co. Ltd